Vident Advisory LLC Has $1.29 Million Stock Position in The Cooper Companies, Inc. $COO

Key Points

• Vident Advisory LLC increased its stake in The Cooper Companies, Inc. by 182.6% during Q1, holding shares worth $1.29 million after acquiring additional shares.
• The company's recent earnings report surpassed expectations, with an EPS of $1.10, beating estimates by $0.03 and showing a 5.7% year-over-year revenue increase.
• Equities analysts have adjusted their price targets for Cooper Companies, with JPMorgan reducing theirs from $76.00 to $66.00 while maintaining a "neutral" rating.

Vident Advisory LLC grew its position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 182.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,288 shares of the medical device company's stock after acquiring an additional 9,878 shares during the quarter. Vident Advisory LLC's holdings in Cooper Companies were worth $1,290,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of COO. Goldman Sachs Group Inc. boosted its position in Cooper Companies by 17.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company's stock worth $399,340,000 after acquiring an additional 686,751 shares during the last quarter. Nuveen LLC acquired a new position in Cooper Companies during the 1st quarter worth approximately $55,367,000. Findlay Park Partners LLP acquired a new position in Cooper Companies during the 1st quarter worth approximately $37,134,000. Price T Rowe Associates Inc. MD boosted its position in Cooper Companies by 12.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,954,877 shares of the medical device company's stock worth $333,595,000 after acquiring an additional 425,400 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Cooper Companies by 8,337.0% during the 1st quarter. SG Americas Securities LLC now owns 369,542 shares of the medical device company's stock worth $31,171,000 after acquiring an additional 365,162 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company's stock.

Insider Activity at Cooper Companies

In other news, COO Daniel G. Mcbride bought 3,000 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The shares were bought at an average price of $65.04 per share, with a total value of $195,120.00. Following the completion of the transaction, the chief operating officer owned 63,120 shares of the company's stock, valued at $4,105,324.80. This trade represents a 4.99% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Brian G. Andrews bought 1,525 shares of the firm's stock in a transaction dated Tuesday, September 2nd. The stock was purchased at an average cost of $65.68 per share, for a total transaction of $100,162.00. Following the transaction, the executive vice president directly owned 22,191 shares of the company's stock, valued at $1,457,504.88. The trade was a 7.38% increase in their position. The disclosure for this purchase can be found here. 1.98% of the stock is currently owned by corporate insiders.

Cooper Companies Stock Performance

COO opened at $67.14 on Thursday. The Cooper Companies, Inc. has a 12-month low of $61.78 and a 12-month high of $112.38. The stock has a market cap of $13.35 billion, a price-to-earnings ratio of 33.07, a PEG ratio of 1.63 and a beta of 0.97. The business has a 50 day moving average of $72.09 and a 200-day moving average of $76.99. The company has a quick ratio of 1.23, a current ratio of 2.12 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.03. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The company had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same period last year, the firm posted $0.96 earnings per share. The business's revenue was up 5.7% on a year-over-year basis. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. On average, equities research analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. JPMorgan Chase & Co. reduced their price target on Cooper Companies from $76.00 to $66.00 and set a "neutral" rating for the company in a research report on Thursday, August 28th. Stifel Nicolaus lowered their price target on Cooper Companies from $90.00 to $85.00 and set a "buy" rating on the stock in a research report on Thursday, August 28th. Morgan Stanley set a $76.00 price target on Cooper Companies and gave the stock an "equal weight" rating in a research report on Thursday, August 28th. Loop Capital set a $100.00 price target on Cooper Companies in a research report on Tuesday, June 17th. Finally, Wall Street Zen cut shares of Cooper Companies from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of "Moderate Buy" and an average price target of $86.64.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.